GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Valuation Rank

BioMerieux (XPAR:BIM) Valuation Rank


View and export this data going back to 2004. Start your Free Trial

What is BioMerieux Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BioMerieux Valuation Rank Related Terms

Thank you for viewing the detailed overview of BioMerieux's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMerieux (XPAR:BIM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Valuation Rank
Comparable Companies
XPAR:ERF XPAR:LBIRD XPAR:ALPRE TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT SHSE:603259 LH DGX RVTY MEDP CRL NTRA
Traded in Other Exchanges
BMXMF:USA BIMp:UK 0RUG:UK EYWN:Germany BIM:Austria
Address
Marcy l’Etoile, Lyon, FRA, 69280
Website
http://www.biomerieux.com
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.